CTalk
Remepy CEO: "We're entering Phase 3 in Parkinson's disease"
After winning CEO of the Year at Tech1, Remepy Co-Founder and Co-CEO Michal Tsur shares the credit and outlines the startup's plans for the future.
Michal Tsur, Co-CEO, Remepy
(Video: Go-Live)
Remepy will be "launching our phase 3 trial early next year" for Parkinson's disease, revealed Remepy Co-Founder and Co-CEO Michal Tsur, who took home the CEO of the Year award at the Tech1 Gala and Awards night. Speaking to CTech’s Amy Shapiro, Tsur clarified that “I’m actually a co-CEO of Remepy, so first thing I would like to dedicate [this] to my other co-CEO, Or Shoval.”
"We're developing hybrid drugs that integrate traditional drugs with AI-driven therapeutic apps that really amplify the effect of the drug," Tsur continued, noting that Parkinson's remains the company's most advanced asset. Looking ahead, Tsur announced that 2027 holds "many partnerships in many therapeutic areas" for the biotech startup, with plans to expand their hybrid therapies across rare oncological diseases, fertility, and immunology
You can watch the full conversation in the video above.
